4'-Halogen Nucleoside Compositions for Broad-Spectrum RNA Virus Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for new compounds and treatments for viral infections, particularly those caused by vector-borne viruses like Eastern and Western Equine Encephalitis and Chikungunya fever, as well as emerging coronaviruses such as SARS-CoV-2, which pose significant health risks and have limited treatment options.
Innovation Solution
Development of halogen-containing nucleotide and nucleoside therapeutic compositions, including conjugates with phosphorus oxides, lipids, and sphingolipids, which target virally encoded RNA-dependent RNA polymerase to treat positive-sense and negative-sense RNA viral infections, and are administered through various routes including pulmonary delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If conventional viral infection treatments are used, then existing treatment options are available, but there is a lack of effective treatments for emerging and vector-borne viruses
Solution Approach 1:
The patent applies universality by developing nucleotide and nucleoside analogs that can target multiple types of viruses including coronaviruses, flaviviruses, arenaviruses, bunyaviruses, and other RNA viruses. The compounds are designed to inhibit viral RNA-dependent RNA polymerase across different viral families, providing a broad-spectrum treatment approach that addresses both emerging and vector-borne viral infections simultaneously
2Adaptability or versatility
If new viral infection treatments are developed, then treatment options for emerging viruses are expanded, but development time and complexity increase
Solution Approach 1:
The patent applies preliminary action by pre-developing a portfolio of nucleotide and nucleoside analogs with known mechanisms of action and safety profiles before the emergence of specific viral threats. This allows for rapid deployment of treatment options when new viruses emerge, as the compounds can be quickly adapted or selected from existing candidates rather than requiring de novo development
3Quantity of substance
If halogen-containing nucleotide and nucleoside compositions are used, then bioavailability is increased, but compound complexity increases
Solution Approach 1:
The patent applies parameter changes by systematically modifying chemical parameters of nucleotide and nucleoside structures, specifically incorporating halogen atoms at the 4' position and varying other structural parameters to optimize bioavailability. These controlled chemical modifications enhance absorption and distribution properties while maintaining manageable structural complexity through systematic rather than random modification approaches
Data Source
AI summary
Disclosed are halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto. In certain embodiments, the disclosure relates to the treatment or prophylaxis of viral infections. Such viral infections can include tongaviridae, bunyaviridae, arenaviridae, coronaviridae, flaviviridae, picornaviridae, Eastern, Western, and Venezuelan Equine Encephalitis (EEE, WEE and VEE, respectively), Chikungunya fever (CHIK), Ebola, Influenza, RSV, and Zika virus infections.